Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

Cancer and Metastasis Reviews

Volumn 34, Issue 3, 2015, Pages 429-441

  Haj Mohammad, N ^a   ter Veer, E ^a   Ngai, L ^a   Mali, R ^a   van Oijen, M G H ^a   van Laarhoven, H W M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Doublet chemotherapy; Esophageal cancer; First line treatment; Gastric cancer; Palliative chemotherapy; Triplet chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CARCINOMA; HUMAN; INFECTION; META ANALYSIS; METASTASIS; METASTATIC ESOPHAGOGASTRIC CARCINOMA; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STOMACH CARCINOMA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; MORTALITY; STOMACH NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84942195697     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9576-y     Document Type: Article

References (47)

1. Al-Batran, S. E., & Ajani, J. A. (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116(11), 2511–8.
2. Murad, A. M., et al. (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72(1), 37–41.
3. Pyrhonen, S., et al. (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer, 71(3), 587–91.
4. Koizumi, W., et al. (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology, 9(3), 215–21.
5. Levi, J. A., et al. (1986). Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. Journal of Clinical Oncology, 4(9), 1348–55.
6. Wagner, A. D., et al. (2010). Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews, 3, CD004064.
7. J. A. and D. A. T. et. al. (2015). National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Gastric Cancer. version 1: Available from: http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
8. Waddell, T., et al. (2013). Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24(Suppl 6), vi57–vi63.
9. Bang, Y. J., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687–97.
10. Koizumi, W., et al. (2013). Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer, 109(8), 2079–86.
11. Ohtsu, A., et al. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 29(30), 3968–76.
12. Cunningham D. et al., (2013). RILOMET-1: an international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced ME-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Journal of Clinical Oncology, 31 (Suppl;abstr TPS4153).
13. Higgins, J.P. and S. Green. (2011). Cochrane Handbook for Systematic Reviews of Interventions.
14. Tierney, J. F., et al. (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.
15. Higgins, J. P., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21(11), 1539–58.
16. Ajani, J. A., et al. (2005). Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. Journal of Clinical Oncology, 23(24), 5660–7.
17. Al-Batran, S. E., et al. (2013). The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). European Journal of Cancer, 49(4), 835–42.
18. Guimbaud, R., et al. (2014). Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. Journal of Clinical Oncology, 32(31), 3520–6.
19. Park, S. H., et al. (2008). Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of Oncology, 19(4), 729–33.
20. Roth, A. D., et al. (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology, 25(22), 3217–23.
21. Van Cutsem, E., et al. (2015). Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology, 26(1), 149–56.
22. Van Cutsem, E., et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology, 24(31), 4991–7.
23. Vanhoefer, U., et al. (2000). Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology, 18(14), 2648–57.
24. Ohtsu, A., Yoshida, S., & Saijo, N. (2006). Disparities in gastric cancer chemotherapy between the East and West. Journal of Clinical Oncology, 24(14), 2188–96.
25. Crew, K. D., & Neugut, A. I. (2006). Epidemiology of gastric cancer. World Journal of Gastroenterology, 12(3), 354–62.
26. Liou, S. Y., et al. (2007). Economic burden of haematological adverse effects in cancer patients: a systematic review. Clinical Drug Investigation, 27(6), 381–96.
27. Funaioli, C., Longobardi, C., & Martoni, A. A. (2008). The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. Journal of Chemotherapy, 20(1), 14–27.
28. Willemse P. H., C. J. Rodenburg, and O. R. (2001). [Een toetssteen voor besluitvorming: nieuwe criteria voor regsistraie oncologische middelen]. Medisch Contact, 56(20): p. 794–6.
29. Ford, H. E., et al. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, 15(1), 78–86.
30. Kim, H. S., et al. (2013). Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Annals of Oncology, 24(11), 2850–4.
31. Thuss-Patience, P. C., et al. (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer, 47(15), 2306–14.
32. Wilke, H., et al. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology, 15(11), 1224–35.
33. Koopman, M., et al. (2007). Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 370(9582), 135–42.
34. Cunningham, D., et al. (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine, 358(1), 36–46.
35. Cullinan, S. A., et al. (1985). A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA, 253(14), 2061–7.
36. Douglass, H. O., Jr., et al. (1984). An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). Journal of Clinical Oncology, 2(12), 1372–81.
37. Kim, N. K., et al. (1993). A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer, 71(12), 3813–8.
38. Kim T., Choi S. J., and e.a. Ahn J. H. (2001). A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5FU (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). Eur J Cancer 37 (Suppl 6;S314).
39. Koizumi, W., et al. (2004). Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer Research, 24(4), 2465–70.
40. Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). (1992). A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4’-epirubicin (FPEPIR). Anticancer Research, 12(6B), 1983–8.
41. Li, X. D., et al. (2011). Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World Journal of Gastroenterology, 17(8), 1082–7.
42. Lin R, et al.,.(2009). Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, leucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol 27 (suppl;abstr e 15642).
43. Maiello E, et al.,(2011). Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (%-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): preliminary results of a randomized. 29 (4 suppl; abstr 97).
44. Roth, A., et al. (1999). High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori, 85(4), 234–8.
45. Thuss-Patience, P. C., et al. (2005). Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. Journal of Clinical Oncology, 23(3), 494–501.
46. Wang, J., et al.,(2015). Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer.
47. Yun, J., et al. (2010). A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. European Journal of Cancer, 46(5), 885–91.